Amyotrophic Lateral Sclerosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

DelveInsight Business Research LLP

DelveInsight’s “Amyotrophic Lateral Sclerosis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Amyotrophic Lateral Sclerosis pipeline landscapes. 

The report comprises Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Amyotrophic Lateral Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Amyotrophic Lateral Sclerosis pipeline products.    

Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a broader group of disorders known as motor neuron diseases, which are caused by gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body. 

Some of the key takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report:

• Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Orion Pharma, Brainstorm-Cell Therapeutics, Orphazyme, MediciNova, Biogen, Biohaven Pharmaceutical, Prilenia Therapeutics, Apellis Pharmaceuticals, etc., are developing therapies for the treatment of Amyotrophic Lateral Sclerosis.

• Emerging therapies such as Levosimendan, NurOwn, Arimoclomol, Ibudilast, Tofersen, Verdiperstat, Pridopidine, AMX0035, Pegcetacoplan, are expected to have a significant impact on the  Amyotrophic Lateral Sclerosis market in the coming years.

Get an overview of pipeline landscape @ Amyotrophic Lateral Sclerosis Clinical Trials Analysis 

Amyotrophic Lateral Sclerosis Pipeline Therapies along with Key Players:

• Levosimendan: Orion Pharma

• NurOwn: Brainstorm-Cell Therapeutics

• Arimoclomol: Orphazyme

• Ibudilast: MediciNova

• Tofersen: Biogen

• Verdiperstat: Biohaven Pharmaceutical

• Pridopidine: Prilenia Therapeutics

• AMX0035: Amylyx

• Pegcetacoplan: Apellis Pharmaceuticals

Scope of Amyotrophic Lateral Sclerosis Pipeline Drug Insight    

• Coverage: Global 

• Major Players: Orion Pharma, Brainstorm-Cell Therapeutics, Orphazyme, MediciNova, Biogen, Biohaven Pharmaceutical, Prilenia Therapeutics, Apellis Pharmaceuticals, and others.

• Pipeline Therapies: Levosimendan, NurOwn, Arimoclomol, Ibudilast, Tofersen, Verdiperstat, Pridopidine, AMX0035, Pegcetacoplan, and others.

Table of Contents

Get a customized pipeline report @ Amyotrophic Lateral Sclerosis Drugs Pipeline Report.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/